Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access study of pasireotide s.c. in patients with Cushing's disease (Seascape)
2010-024165-44Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2011
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pasireotide LAR in Corticotropin adenoma (ACTHoma), sponsored by Novartis. Primary endpoint: Drug-related grade 3/4 or serious adverse events. Started May 2011; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2010-024165-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024165-44.